Atezolizumab vs Single-Agent Chemo in NSCLC Patients Ineligible for a 1L Platinum Regimen: Asian Subgroup Analysis of IPSOS

被引：0

作者：

Lee, S. M. ^{[1
]}

Han, B. ^{[2
]}

Peters, S. ^{[3
]}

Le, A. T. ^{[4
]}

Huang, D. ^{[5
]}

Wu, G. ^{[6
]}

Cao, L. ^{[7
]}

Pham, C. P. ^{[8
]}

Zhao, J. ^{[9
]}

Wang, K. ^{[10
]}

Yang, N. ^{[11
]}

Zhong, H. ^{[2
]}

Hu, Y. ^{[12
]}

Morris, S. ^{[12
]}

Lam, V. ^{[13
]}

Graupner, V. ^{[12
]}

Gitlitz, B. ^{[13
]}

Hoglander, E. ^{[12
]}

Schulz, C. ^{[14
]}

机构：

[1] Univ Coll London Hosp NHS Fdn Trust, London, England

[2] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai, Peoples R China

[3] Univ Lausanne, CHU Vaudois, Lausanne, Switzerland

[4] Cho Ray Hosp, Cho Ray Canc Ctr, Ho Chi Minh City, Vietnam

[5] Tianjin Med Univ, Tianjin, Peoples R China

[6] Huazhong Univ, Tongji Med Coll, Wuhan, Peoples R China

[7] Anhui Prov Hosp, Hefei, Peoples R China

[8] Bach Mai Hosp, Nucl Med & Oncol Ctr, Hanoi, Vietnam

[9] Beijing Canc Hosp, Beijing, Peoples R China

[10] Zhejiang Univ, Affiliated Hosp 2, Sch Med, Hangzhou, Peoples R China

[11] Hunan Canc Hosp, Changsha, Peoples R China

[12] F Hoffmann La Roche Ltd, Basel, Switzerland

[13] Genentech Inc, San Francisco, CA USA

[14] Univ Hosp Regensburg, Regensburg, Germany

来源：

JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期

关键词：

IPSOS; Atezolizumab; Asian subgroup;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

EP11.02-06

引用

页码：S616 / S617

页数：2

共 50 条

[31] Nivolumab (N) plus Low-Dose Ipilimumab (I) vs Platinum-Doublet Chemotherapy (Chemo) as First-Line (1L) Treatment (tx) for Advanced Non-Small Cell Lung Cancer (NSCLC): Checkmate 227 Part 1 Final Analysis
Reck, Martin
Peters, Solange
Ramalingam, Suresh
Paz-Ares, Luis
Bernabe Caro, Reyes
Zurawski, Bogdan
Kim, Sang-We
Alexandru, Aurelia
Lupinacci, Lorena
de la Mora Jitnenez, Emmanuel
Sakai, Hiroshi
Albert, Istvan
Vergnenegre, Alain
Borghaei, Hossein
Brahmer, Julie R.
O'byrne, Kenneth
Geese, William J.
Bhagavatheeswaran, Prabhu
Nattan, Faith E.
Hellmann, Matthew D.
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 233 - 234
[32] First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients (pts) with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 Chinese subgroup analysis with 3-year follow-up.
Shen, Lin
Bai, Yuxian
Lin, Xiaoyan
Li, Wei
Wang, Jufeng
Zhang, Xiaochun
Pan, Hongming
Bai, Chunmei
Bai, Li
Cheng, Ying
Zhang, Jingdong
Zhong, Haijun
Ba, Yi
Hu, Wenwei
Xu, Rui-Hua
Guo, Weijian
Qin, Shukui
Wang, Rui
Sullivan, Kendall
Liu, Tianshu
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 353 - 353
[33] EMPOWER-Lung 1: Phase III first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) ≥50%
Sezer, A.
Kilickap, S.
Gumus, M.
Bondarenko, I.
Ozguroglu, M.
Gogishvili, M.
Turk, H. M.
Cicin, I.
Bentsion, D.
Gladkov, O.
Clingan, P.
Sriuranpong, V.
Rizvi, N.
Li, S.
Lee, S.
Gullo, G.
Lowy, I.
Rietschel, P.
ANNALS OF ONCOLOGY, 2020, 31 : S1388 - S1388
[34] EMPOWER-Lung 1: Phase III first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) ≥50%
Sezer, A.
Kilickap, S.
Gumus, M.
Bondarenko, I.
Ozguroglu, M.
Gogishvili, M.
Turk, H. M.
Cicin, I.
Bentsion, D.
Gladkov, O.
Clingan, P.
Sriuranpong, V.
Rizvi, N.
Li, S.
Lee, S.
Gullo, G.
Lowy, I.
Rietschel, P.
ANNALS OF ONCOLOGY, 2020, 31 : S1182 - S1183
[35] IMvigor130: A randomized, phase III study evaluating first-line (1L) atezolizumab (atezo) as monotherapy and in combination with platinum-based chemotherapy (chemo) in patients (pts) with locally advanced or metastatic urothelial carcinoma (mUC).
Galsky, Matt D.
Grande, Enrique
Davis, Ian D.
De Santis, Maria
Arija, Jose Angel Arranz
Kikuchi, Eiji
Mecke, Almut
Thastrom, Ann Christine
Bamias, Aristotelis
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[36] Immune-related adverse events (irAEs) with single-agent PD-1 vs PD-L1 inhibitors: A meta-analysis of 8,730 patients from clinical trials
Sonpavde, G. P.
Grivas, P.
Lin, Y.
Hennessy, D.
Hunt, J. D.
ANNALS OF ONCOLOGY, 2019, 30
[37] First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients (pts) with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 Chinese subgroup analysis 4-year (yr) follow-up
Shen, Lin
Bai, Yuxian
Lin, Xiaoyan
Li, Wei
Wang, Jufeng
Zhang, Xiaochun
Pan, Hongming
Bai, Chunmei
Bai, Li
Cheng, Ying
Zhang, Jingdong
Zhong, Haijun
Ba, Yi
Hu, Wenwei
Xu, Rui-Hua
Guo, Weijian
Qin, Shukui
Wang, Rui
McCraith, Stephen
Liu, Tianshu
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 318 - 318
[38] Nivolumab (NIVO) plus platinum-doublet chemotherapy (chemo) vs chemo as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (aNSCLC): CheckMate 227-part 2 final analysis
Paz-Ares, L.
Ciuleanu, T. E.
Yu, X.
Salman, P.
Pluzanski, A.
Nagrial, A.
Havel, L.
Kowalyszyn, R.
Audigier-Valette, C.
Wu, Y-L.
Borghaei, H.
Hellmann, M. D.
Brahmer, J.
Reck, M.
Ramalingam, S.
Zhang, L.
Bhagavatheeswaran, P.
Nathan, F. E.
O'Byrne, K. J.
ANNALS OF ONCOLOGY, 2019, 30 : 67 - 68
[39] RATIONALE 304: Tislelizumab (TIS) plus chemotherapy (chemo) vs chemo alone as first-line (1L) treatment for non-squamous (non-sq) non-small cell lung cancer (NSCLC) in patients (pts) who are smokers vs non-smokers
Lu, S.
Huang, D.
Chen, X.
Wang, B.
Xue, J.
Wang, J.
Bao, Y.
Liang, L.
Qiu, X.
Zhang, L.
ANNALS OF ONCOLOGY, 2021, 32 : S1000 - S1001
[40] First-Line (1L) nivolumab (NIVO) plus chemotherapy (chemo) versus chemo in patients (pts) with advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 Chinese subgroup analysis.
Shen, Lin
Bai, Yuxian
Lin, Xiaoyan
Li, Wei
Wang, Jufeng
Zhang, Xiaochun
Pan, Hongming
Bai, Chunmei
Bai, Li
Cheng, Ying
Zhang, Jingdong
Zhong, Haijun
Ba, Yi
Hu, Wenwei
Xu, Ruihua
Guo, Weijian
Qin, Shukui
Yang, Nong
Lu, Jianwei
Shitara, Kohei
Lei, Ming
Li, Mingshun
Bao, Nicole
Chen, Tian
Liu, Tianshu
CANCER RESEARCH, 2021, 81 (13)

← 1 2 3 4 5 →